Literature DB >> 11754196

Steroid treatment for myasthenia gravis: steroids have an important role.

Richard S Bedlack1, Donald B Sanders.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11754196     DOI： 10.1002/mus.1221

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  7 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 2.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

Review 3.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

Review 4.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

5.  Efficacy of perioperative high-dose prednisolone therapy during thymectomy in myasthenia gravis patients.

Authors:  Yoshito Yamada; Shigetoshi Yoshida; Hidemi Suzuki; Tetsuzo Tagawa; Takekazu Iwata; Teruaki Mizobuchi; Naoki Kawaguchi; Ichiro Yoshino
Journal:  J Cardiothorac Surg       Date:  2013-12-10       Impact factor: 1.637

6.  Clinical Predictors of Relapse in a Cohort of Steroid-Treated Patients With Well-Controlled Myasthenia Gravis.

Authors:  Shengyao Su; Lin Lei; Zhirong Fan; Shu Zhang; Qi Wen; Jingsi Wang; Yan Lu; Li Di; Min Wang; Hai Chen; Yuwei Da
Journal:  Front Neurol       Date:  2022-02-04       Impact factor: 4.003

7.  Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis.

Authors:  Laura Díez-Porras; Christian Homedes; Maria Antonia Alberti; Valentina Vélez-Santamaría; Carlos Casasnovas
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.